Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Profund Advisors LLC

Profund Advisors LLC lowered its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 10.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 47,087 shares of the biotechnology company’s stock after selling 5,715 shares during the quarter. Profund Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,679,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. North Star Investment Management Corp. acquired a new stake in Arrowhead Pharmaceuticals during the second quarter worth approximately $29,000. KBC Group NV acquired a new stake in Arrowhead Pharmaceuticals during the second quarter worth approximately $32,000. Advisors Asset Management Inc. boosted its position in Arrowhead Pharmaceuticals by 94.6% during the first quarter. Advisors Asset Management Inc. now owns 720 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 350 shares during the last quarter. Captrust Financial Advisors boosted its holdings in shares of Arrowhead Pharmaceuticals by 22.4% in the 2nd quarter. Captrust Financial Advisors now owns 1,201 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 220 shares during the last quarter. Finally, TCI Wealth Advisors Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 25.6% in the 1st quarter. TCI Wealth Advisors Inc. now owns 2,127 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 433 shares during the last quarter. Institutional investors and hedge funds own 65.98% of the company’s stock.

Insider Buying and Selling

In other news, Director Victoria Vakiener sold 1,550 shares of the business’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $26.33, for a total value of $40,811.50. Following the completion of the sale, the director now owns 21,734 shares of the company’s stock, valued at approximately $572,256.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Victoria Vakiener sold 1,550 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $26.33, for a total value of $40,811.50. Following the completion of the transaction, the director now directly owns 21,734 shares of the company’s stock, valued at approximately $572,256.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Richard Anzalone sold 57,755 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $28.12, for a total transaction of $1,624,070.60. Following the completion of the transaction, the chief executive officer now directly owns 3,761,338 shares of the company’s stock, valued at $105,768,824.56. The disclosure for this sale can be found here. Insiders have sold 83,643 shares of company stock valued at $2,254,105 in the last quarter. Company insiders own 5.00% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $28.90 on Tuesday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $22.87 and a 12-month high of $42.48. The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of -16.90 and a beta of 0.89. The firm’s fifty day moving average price is $26.44 and its 200 day moving average price is $31.10.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. StockNews.com upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, August 9th. Citigroup assumed coverage on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 19th. They issued a “neutral” rating and a $33.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $47.00 price target (down previously from $79.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, August 8th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, August 8th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $54.53.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis.